The global market for neurodegenerative drugs is projected to grow from $27.2bn in 2015 to $45bn by 2022, according to a report by GBI Research.
Titled ‘Global Neurodegenerative Drugs Market to 2022’, the report forecasts the neurodegenerative disorders market to grow at a compound annual growth rate of 7.42%.
The majority of the growth is expected to occur between 2018 and 2022 with the approval of a number of pipeline products. A total of 1,494 products are currently in active development in the neurodegenerative disorders space, most of which are novel drugs, while the remaining are either generics or repositioned products.
Late-stage products currently under development, including ocrelizumab, ozanimod, solanezumab, ITI-007 and RG-7412, are expected to be commercially successful.
Leading players such as Biogen, Novartis and Sanofi are expected to maintain their position in the market despite impending patent expiries of Biogen’s Tysabri and Novartis’ Gilenya, which are expected to affect sales, according to GBI Research analyst Qaisrah Khalid.
Revenues from Teva’s Copaxone (glatiramer acetate) are expected to decrease from $4bn in 2015 to $2.5bn by 2022, following patent expiry in 2014. Approval of ocrelizumab, however, is expected to boost Roche’s revenues and establishing it as the leading player in the market, adds Khalid.